Showing results (11-20 of 274) with videos related to

Sort By:
Pageof 28
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1994
In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophagesJ L Masferrer, S T Reddy, B S Zweifel, et al.
Gastroenterology Clinics of North America|June 1, 1996
Cyclooxygenase-2 inhibitors: a new class of anti-inflammatory agents that spare the gastrointestinal tractJ L Masferrer, P C Isakson, K Seibert
The Journal of Clinical Investigation|July 1, 1995
Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitorsD Salvemini, P T Manning, B S Zweifel, et al.
Anticancer Research|February 19, 2002
Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesisH M Abou-Issa, G A Alshafie, K Seibert, et al.
The Journal of Comparative Neurology|August 15, 1992
Distribution and characterization of cyclooxygenase immunoreactivity in the ovine brainC D Breder, W L Smith, A Raz, et al.
The Journal of Experimental Medicine|September 1, 1996
Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivoJ P Portanova, Y Zhang, G D Anderson, et al.
Biochemical and Biophysical Research Communications|May 15, 1991
Post-translational processing and secretory pathway of human atriopeptin in rat pheochromocytoma cellsS Shiono, N Suganuma, M Bo, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 12, 1994
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenicJ L Masferrer, B S Zweifel, P T Manning, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|June 8, 2002
Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancersA T Koki, N K Khan, B M Woerner, et al.
Survey of Ophthalmology|February 1, 1997
Cyclooxygenase-2 inhibitors: a new approach to the therapy of ocular inflammationJ L Masferrer, P S Kulkarni
Pageof 28